Recent Updates
Recently added Catalysts
CRL Positive Sentiment

Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development

Key Takeaway: Charles River Laboratories has partnered with Magellan Stem Cells to enhance the development of stem cell-based therapies. This collaboration will utilize Charles River's expertise in biologics quality control and cGMP practices. The goal is to advance clinical applications in regenerative medicine, benefiting both companies and the broader healthcare sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration aims to advance stem cell therapies.
  • Combines expertise of Charles River and Magellan Stem Cells.
  • Focus on regenerative medicine solutions.

Full Press Release Details

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r

Frequently Asked Questions

What is the purpose of the collaboration?

The collaboration aims to support the development of stem cell-based therapies.

Who are the partners in this collaboration?

Charles River Laboratories and Magellan Stem Cells are the partners.

What expertise does Charles River bring?

Charles River offers specialized expertise in biologics quality control and cGMP practices.

What field does this collaboration focus on?

The focus is on advancing regenerative medicine solutions.

Last updated: Oct 13, 2026